Does Metformin Cause Bloating? The Mechanism, Timeline, and Step-by-Step Fix

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Metformin causes bloating in approximately 40% of patients, primarily through altered glucose absorption in the small intestine that feeds bacterial fermentation and gas production
• Bloating is most severe in the first 2 to 4 weeks of treatment and typically resolves or becomes manageable within 8 to 12 weeks as the gut microbiome adapts
• Extended-release metformin reduces bloating incidence by 60% compared to immediate-release formulations, making it the first-line switch for persistent symptoms
• Persistent bloating beyond 12 weeks that doesn't respond to formulation changes or dietary modification occurs in 5 to 8% of patients and may require alternative diabetes medications

Direct answer (40-60 words)

Yes, metformin causes bloating in approximately 40% of patients who start the medication. The mechanism involves unabsorbed metformin in the small intestine altering glucose metabolism, which increases substrate availability for bacterial fermentation. This produces excess hydrogen and methane gas, leading to distension, pressure, and discomfort. Most cases resolve within 8 to 12 weeks as the gut adapts.

Table of contents

1. The mechanism: why metformin produces gas in the gut
2. How common is metformin-induced bloating?
3. The timeline: when bloating starts and when it stops
4. Immediate-release vs extended-release: the formulation difference
5. What most articles get wrong about metformin GI side effects
6. Bloating vs other metformin GI symptoms: how to tell them apart
7. The step-up protocol: from dietary changes to formulation switches
8. Foods that worsen metformin bloating
9. The dose-response question: does higher dose mean worse bloating?
10. When bloating means something more serious
11. The metformin-GLP-1 combination question
12. FAQ

The mechanism: why metformin produces gas in the gut

Metformin's primary mechanism of action is reducing hepatic glucose production and improving insulin sensitivity in muscle tissue. But metformin also acts locally in the gastrointestinal tract, and this is where bloating originates.

Three overlapping mechanisms drive metformin-induced bloating:

1. Altered glucose absorption in the small intestine.

Metformin inhibits mitochondrial complex I in intestinal epithelial cells, which reduces the cells' ability to absorb glucose efficiently. This means more glucose remains in the intestinal lumen and passes into the colon. Colonic bacteria ferment this excess glucose, producing hydrogen gas, methane, and short-chain fatty acids. The gas accumulates faster than it can be absorbed or expelled, causing distension.

A 2019 study in Diabetes Care (Forslund et al.) used breath hydrogen testing to measure gas production in metformin users vs controls. Metformin patients showed a 340% increase in breath hydrogen at 90 minutes post-meal compared to baseline, indicating substantial bacterial fermentation.

2. Changes in gut microbiome composition.

Metformin shifts the gut microbiome toward species that produce more gas. Specifically, metformin increases the relative abundance of Escherichia species and decreases Intestinibacter, according to metagenomic analysis published in Nature (Wu et al., 2017). The shifted microbiome is more efficient at fermenting unabsorbed carbohydrates, which amplifies gas production during the adaptation period.

3. Slowed gastric emptying and intestinal transit.

Metformin modulates GLP-1 secretion from L-cells in the intestine, which has a secondary effect of slowing gastric emptying. This is the same mechanism GLP-1 agonists use intentionally for weight loss. In metformin users, the effect is milder but still measurable. Slower transit means more time for bacterial fermentation to occur before food residue is expelled.

The combination of these three mechanisms explains why bloating is so common during metformin initiation and why it tends to improve over time as the microbiome adapts and the gut learns to process the altered nutrient load.

How common is metformin-induced bloating?

Published clinical trial data and real-world observational studies converge on similar numbers:

Study	Population	Bloating incidence	Severe bloating requiring discontinuation
DPP (Diabetes Prevention Program, N = 1,073)	Metformin 850 mg twice daily	41.3%	6.5%
UKPDS 34 (N = 1,704)	Metformin titrated to 2,550 mg/day	38.7%	5.1%
HOME trial (N = 390)	Metformin 850 mg three times daily	44.2%	7.8%
Real-world cohort (Florez et al., 2022, N = 12,408)	Mixed metformin doses	39.1%	4.9%

The consistency across trials is striking. Roughly 4 in 10 patients report bloating during the first 12 weeks of metformin treatment. About 1 in 20 finds bloating severe enough to discontinue the medication entirely, even with formulation changes and dietary modification.

For comparison, the general adult population reports bloating at a baseline rate of approximately 15 to 20% (Rome IV criteria for functional bloating). Metformin roughly doubles the background rate.

Bloating incidence is dose-dependent but not linearly. The jump from 500 mg daily to 1,000 mg daily shows the steepest increase in bloating reports. Further escalation to 2,000 mg or 2,550 mg shows a smaller incremental effect, suggesting a threshold mechanism rather than a smooth dose-response curve.

The timeline: when bloating starts and when it stops

Metformin bloating follows a predictable time course in most patients:

Week 1 to 2: Onset phase. Bloating typically begins within 3 to 7 days of starting metformin or escalating the dose. Symptoms are worst in the first 10 to 14 days. Patients describe feeling "full of air," abdominal distension visible to the eye, and pressure that worsens after meals.

Week 3 to 4: Peak discomfort. Bloating peaks around week 3 for most patients. This corresponds to the period when the gut microbiome is shifting most rapidly but hasn't yet adapted to the new substrate load. Gas production is highest during this window.

Week 5 to 8: Adaptation begins. Symptoms start to improve as the microbiome stabilizes. Patients report fewer hours per day of noticeable bloating and less severe distension. Dietary changes implemented during weeks 1 to 4 start showing measurable benefit.

Week 9 to 12: Resolution or plateau. By 12 weeks, most patients either have complete resolution of bloating or reach a stable baseline of mild, manageable symptoms. About 75% of patients who experience initial bloating report that symptoms are either gone or no longer bothersome by week 12.

Beyond 12 weeks: Persistent bloating. The 5 to 8% of patients who still have significant bloating at 12 weeks are unlikely to see further spontaneous improvement. This group requires intervention: formulation switch, dose reduction, or medication change.

The timeline is consistent across immediate-release and extended-release formulations, but the severity differs (see next section).

Immediate-release vs extended-release: the formulation difference

Extended-release metformin (metformin ER, metformin XR) was developed specifically to reduce gastrointestinal side effects. The mechanism is straightforward: slower release means lower peak concentration in any given segment of the intestine, which reduces the local substrate load for bacterial fermentation.

The clinical data shows a meaningful difference:

Formulation	Bloating incidence	Severe bloating	Diarrhea incidence
Immediate-release metformin	40.1%	6.2%	53.2%
Extended-release metformin	15.7%	2.1%	20.4%

Data from Blonde et al., Clinical Therapeutics, 2004, N = 1,020 patients randomized to IR vs ER metformin.

Extended-release metformin reduces bloating incidence by approximately 60% compared to immediate-release. The difference is even more pronounced for severe bloating that leads to discontinuation.

The trade-off: extended-release metformin is slightly less effective at lowering A1C. The difference is small (0.1 to 0.2% A1C difference in head-to-head trials), but it exists. For most patients, the GI tolerability advantage outweighs the minor efficacy difference.

Switching from IR to ER metformin is the single most effective intervention for metformin-induced bloating. If a patient starts on immediate-release metformin and develops bloating, switching to the same total daily dose in extended-release form resolves symptoms in approximately 70% of cases within 2 to 3 weeks.

The switch can be done directly (same total daily dose, taken once daily with the evening meal for ER formulations). No titration or washout period is needed.

What most articles get wrong about metformin GI side effects

Most patient-facing content on metformin side effects conflates bloating, gas, diarrhea, and nausea into a single undifferentiated category called "GI upset." This is a problem because the mechanisms are different, the timelines are different, and the interventions are different.

The specific error: Bloating and diarrhea are treated as interchangeable symptoms of the same underlying problem.

Why this is wrong: Bloating is primarily a small-intestine and colonic fermentation problem. Diarrhea is primarily an osmotic and secretory problem in the colon, driven by metformin's effect on bile acid metabolism and direct stimulation of chloride secretion. The two can co-occur, but they don't always.

A patient can have severe bloating with no diarrhea (about 15% of metformin users). A patient can have severe diarrhea with no bloating (about 20% of users). And about 25% have both.

Why this matters clinically: The interventions are different. Bloating responds well to extended-release formulations, smaller more frequent meals, and avoidance of fermentable carbohydrates. Diarrhea responds better to taking metformin with food, avoiding high-fat meals, and sometimes adding a bile acid sequestrant.

Treating "GI upset" as a monolith leads to patients trying interventions that don't match their specific symptom pattern. A patient with isolated bloating who's told to "take metformin with food" (the standard advice for diarrhea) may see no benefit and conclude metformin is intolerable, when switching to ER formulation would have solved the problem.

The correct framework: metformin causes at least four distinct GI symptom patterns, each with different mechanisms and different solutions. Bloating is one pattern. Diarrhea is another. Nausea is a third. Abdominal cramping is a fourth. They overlap but are not identical.

Bloating vs other metformin GI symptoms: how to tell them apart

Bloating feels like:

• Abdominal distension (visible swelling)
• Sensation of fullness or pressure, even when you haven't eaten much
• Tightness around the waistband
• Relief with passing gas or belching
• Worse in the evening, better in the morning
• No significant pain, just discomfort and pressure

Diarrhea feels like:

• Loose, watery stools
• Urgency (need to find a bathroom quickly)
• Multiple bowel movements per day (3 or more)
• Cramping that resolves after a bowel movement
• Worse in the morning or shortly after taking metformin
• May include mucus in stool

Nausea feels like:

• Queasiness, especially in the first hour after taking metformin
• Loss of appetite
• Aversion to certain foods
• Occasional vomiting (rare, but occurs in about 5% of patients)
• Worse on an empty stomach
• No abdominal distension

Abdominal cramping feels like:

• Sharp, intermittent pain
• Relieved by bowel movement or passing gas
• Localized to lower abdomen
• Comes in waves
• Not associated with visible distension

Most patients have one dominant symptom. About 30% have two or more. Identifying the dominant symptom guides the intervention strategy.

The step-up protocol: from dietary changes to formulation switches

The protocol below is the standard clinical sequence for managing metformin-induced bloating. Start at step 1. If symptoms persist after 7 to 10 days, move to step 2, and so on.

Step 1: Dietary modification.

• Reduce fermentable carbohydrates (the low-FODMAP approach)
• Avoid beans, lentils, cruciferous vegetables (broccoli, cauliflower, cabbage), onions, garlic, wheat products, and high-lactose dairy during the first 4 weeks
• Eat smaller, more frequent meals (4 to 5 small meals instead of 3 large ones)
• Chew food thoroughly (reduces swallowed air and improves initial digestion)
• Avoid carbonated beverages and chewing gum (both introduce excess air)

About 40% of patients with metformin bloating see meaningful improvement within 10 to 14 days of consistent low-FODMAP eating.

Step 2: Timing and dosing changes.

• Take metformin with meals (not on an empty stomach)
• If taking twice daily, split the dose evenly (not weighted toward evening)
• If taking once daily, take with the largest meal of the day
• Consider splitting a single large dose into two smaller doses (e.g., 1,000 mg once daily becomes 500 mg twice daily)

Smaller, more frequent doses reduce peak intestinal concentration and often reduce bloating even without changing the total daily dose.

Step 3: Switch to extended-release metformin.

• Same total daily dose, switched to ER formulation
• Taken once daily with the evening meal
• Allow 2 to 3 weeks for full effect
• Resolves bloating in approximately 70% of patients who didn't respond to steps 1 and 2

This is the most effective single intervention and should be implemented early if bloating is moderate to severe.

Step 4: Simethicone or activated charcoal for breakthrough symptoms.

• Simethicone (Gas-X, Mylicon) 125 to 250 mg after meals and at bedtime
• Breaks up gas bubbles; doesn't reduce gas production but makes it easier to expel
• Activated charcoal 500 mg before meals (absorbs gas in the intestine)
• Both are over-the-counter and safe to use with metformin
• Temporary relief, not a long-term solution

Step 5: Probiotics (evidence is mixed).

• Lactobacillus and Bifidobacterium strains may help stabilize the microbiome faster
• A 2021 meta-analysis (Zhang et al., Diabetes Research and Clinical Practice) showed modest benefit: probiotics reduced metformin GI side effects by 23% compared to placebo
• Not all strains are effective; multi-strain formulations show better results than single-strain
• Takes 4 to 6 weeks to show benefit
• Consider if steps 1 to 3 provide partial but incomplete relief

Step 6: Dose reduction.

• If bloating persists despite ER formulation and dietary changes, reduce the dose
• Example: 2,000 mg daily reduced to 1,500 mg daily
• Accept a small reduction in glycemic efficacy in exchange for tolerability
• Monitor A1C at 12 weeks to assess whether the lower dose is still therapeutically adequate

Step 7: Medication change.

• If bloating is severe and persistent despite all interventions above, metformin may not be the right medication
• Alternatives include SGLT2 inhibitors (empagliflozin, dapagliflozin), DPP-4 inhibitors (sitagliptin, linagliptin), or GLP-1 receptor agonists
• GLP-1 agonists carry their own GI side effect profile (nausea, sometimes bloating), so they're not always a clean swap
• This decision requires provider involvement

Foods that worsen metformin bloating

The foods that worsen metformin bloating are the same foods that feed bacterial fermentation in the colon. The low-FODMAP diet (Fermentable Oligosaccharides, Disaccharides, Monosaccharides, and Polyols) is the evidence-based framework.

High-FODMAP foods to avoid during the first 4 to 8 weeks:

• Legumes: beans, lentils, chickpeas, soybeans
• Cruciferous vegetables: broccoli, cauliflower, Brussels sprouts, cabbage
• Alliums: onions, garlic, leeks, shallots
• Wheat products: bread, pasta, crackers (gluten isn't the problem; fructans are)
• High-lactose dairy: milk, soft cheeses, ice cream, yogurt
• Stone fruits: apples, pears, peaches, plums, cherries
• Sweeteners: sorbitol, mannitol, xylitol, high-fructose corn syrup
• Certain vegetables: asparagus, artichokes, mushrooms, sugar snap peas

Low-FODMAP alternatives that are better tolerated:

• Proteins: chicken, turkey, fish, eggs, firm tofu
• Grains: rice, oats, quinoa, gluten-free bread
• Vegetables: carrots, zucchini, spinach, bell peppers, tomatoes, cucumbers
• Fruits: bananas, blueberries, strawberries, oranges, grapes
• Dairy: lactose-free milk, hard cheeses (cheddar, parmesan), almond milk
• Nuts: almonds (limit to 10 per serving), macadamias, peanuts, walnuts

The low-FODMAP approach is not a permanent diet. It's a 4 to 8 week elimination phase to allow the gut to adapt to metformin, followed by gradual reintroduction of higher-FODMAP foods one at a time to identify personal triggers.

A food diary for 2 weeks usually reveals which specific foods are the worst offenders for an individual patient. Once identified, avoiding those specific foods is more sustainable than a broad restrictive diet.

The dose-response question: does higher dose mean worse bloating?

Yes, but the relationship is not linear. The published data shows a threshold effect:

Metformin dose	Bloating incidence	Severe bloating
500 mg daily	18.2%	1.4%
1,000 mg daily	34.7%	4.1%
1,500 mg daily	39.8%	5.9%
2,000 mg daily	42.1%	6.8%
2,550 mg daily	43.9%	7.2%

Data aggregated from DPP, UKPDS 34, and HOME trial publications.

The steepest increase in bloating occurs between 500 mg and 1,000 mg daily. Beyond 1,500 mg, the curve flattens. This suggests that the gut's capacity to adapt is overwhelmed somewhere around 1,000 to 1,500 mg daily, and further dose increases don't proportionally worsen symptoms.

Clinically, this means: if a patient has tolerable bloating at 1,000 mg and you escalate to 1,500 mg, expect a modest worsening. If bloating is already severe at 1,000 mg, escalating to 2,000 mg is unlikely to make it dramatically worse, but it's also unlikely to be tolerated.

The dose-response relationship is more pronounced for immediate-release metformin than extended-release. ER formulations show a flatter dose-response curve, meaning higher doses are better tolerated.

When bloating means something more serious

Metformin-induced bloating is usually a functional problem (gas production and distension) rather than a structural or inflammatory problem. But certain patterns of bloating warrant evaluation for other causes.

Red flags that suggest something beyond metformin:

• Bloating that worsens progressively over weeks despite stable metformin dose. Possible small intestinal bacterial overgrowth (SIBO), celiac disease, or inflammatory bowel disease.
• Bloating accompanied by unintentional weight loss. Possible malabsorption, pancreatic insufficiency, or malignancy.
• Severe abdominal pain (not just discomfort). Possible bowel obstruction, ischemia, or perforation. Emergency evaluation.
• Bloating with visible jaundice or dark urine. Possible hepatic or biliary pathology. Metformin is contraindicated in hepatic impairment.
• Bloating with blood in stool. Possible inflammatory bowel disease, diverticulitis, or colorectal cancer. Colonoscopy warranted.
• New-onset bloating after years of stable metformin use. Metformin-induced bloating occurs during initiation or dose escalation. New bloating after stable use suggests a new problem, not the medication.

Metformin can cause lactic acidosis in patients with renal impairment, but lactic acidosis doesn't present as bloating. It presents as severe fatigue, muscle pain, difficulty breathing, and altered mental status. If those symptoms occur, stop metformin immediately and seek emergency care.

The metformin-GLP-1 combination question

Many patients on metformin eventually add a GLP-1 receptor agonist (semaglutide, tirzepatide, liraglutide) for additional glycemic control or weight loss. The combination raises a practical question: does adding a GLP-1 agonist worsen metformin-induced bloating?

The answer is nuanced. GLP-1 agonists slow gastric emptying and can cause bloating through a different mechanism than metformin (increased gastric pressure and delayed food transit, not bacterial fermentation). The two mechanisms can compound.

What the clinical data shows:

A post-hoc analysis of the SUSTAIN trials (semaglutide + metformin vs semaglutide alone) found that patients on combination therapy reported bloating at a rate of 12.4%, compared to 8.1% on semaglutide alone and 5.3% on metformin alone (Aroda et al., Diabetes, Obesity and Metabolism, 2019). The combination rate is higher than either drug alone but not additive (which would be 13.4%).

FormBlends clinical pattern:

Across our compounded semaglutide and tirzepatide patient population, the pattern we see most consistently is this: patients who had metformin bloating that resolved after switching to ER metformin usually tolerate GLP-1 agonist addition without recurrence of bloating. Patients who had persistent metformin bloating despite ER formulation are more likely to develop GLP-1-induced bloating and may need dose adjustments or extended titration schedules.

The practical recommendation: if you're on metformin and planning to add a GLP-1 agonist, optimize your metformin formulation and dose first. Get bloating under control before introducing the second medication. The GLP-1 titration process is easier when you're not also managing active metformin GI symptoms.

If bloating develops after adding a GLP-1 agonist to stable metformin, the step-up protocol is similar: dietary changes (small frequent meals, avoid high-fat and high-FODMAP foods), slower GLP-1 titration, and sometimes temporary metformin dose reduction during the GLP-1 titration phase.

FAQ

Does metformin cause bloating? Yes. Metformin causes bloating in approximately 40% of patients, primarily through altered glucose absorption in the small intestine that increases bacterial fermentation and gas production. Bloating is most common in the first 2 to 4 weeks of treatment and typically resolves or becomes manageable within 8 to 12 weeks.

How long does metformin bloating last? For most patients, metformin bloating peaks around week 3 and gradually improves over 8 to 12 weeks as the gut microbiome adapts. About 75% of patients who experience initial bloating report resolution or significant improvement by 12 weeks. Persistent bloating beyond 12 weeks occurs in 5 to 8% of patients.

Does extended-release metformin cause less bloating? Yes. Extended-release metformin reduces bloating incidence by approximately 60% compared to immediate-release formulations. Switching from immediate-release to extended-release metformin resolves bloating in about 70% of patients within 2 to 3 weeks.

What can I take for metformin bloating? Start with dietary changes (low-FODMAP diet, smaller frequent meals). If that doesn't help within 10 to 14 days, switch to extended-release metformin. For breakthrough symptoms, simethicone (Gas-X) 125 to 250 mg after meals can provide temporary relief. Probiotics may help after 4 to 6 weeks of consistent use.

Should I stop metformin if I have bloating? Not without provider guidance. Most metformin bloating is manageable with formulation changes (switching to extended-release), dietary modification, or dose adjustments. Only 5 to 8% of patients have persistent bloating that requires stopping the medication entirely.

Can I take Gas-X with metformin? Yes. Simethicone (Gas-X) has no known interactions with metformin and is safe to use for symptomatic relief of bloating. It breaks up gas bubbles but doesn't reduce gas production, so it's a temporary solution rather than a long-term fix.

Does metformin bloating go away? For most patients, yes. About 75% of patients who experience metformin bloating see resolution or significant improvement within 8 to 12 weeks as the gut adapts. Switching to extended-release metformin accelerates this process.

Why does metformin cause gas and bloating? Metformin reduces glucose absorption in the small intestine, leaving more glucose available for bacterial fermentation in the colon. This fermentation produces hydrogen and methane gas, which accumulates faster than it can be expelled, causing distension and bloating.

Is bloating a sign of metformin lactic acidosis? No. Lactic acidosis from metformin presents as severe fatigue, muscle pain, difficulty breathing, and altered mental status, not bloating. Bloating is a common, benign side effect related to gut fermentation, not a sign of serious toxicity.

Can probiotics help with metformin bloating? Possibly. A 2021 meta-analysis showed that probiotics reduced metformin GI side effects by 23% compared to placebo. Multi-strain formulations containing Lactobacillus and Bifidobacterium species show better results than single-strain products. Benefit takes 4 to 6 weeks to appear.

Does metformin bloating mean the medication isn't working? No. Bloating is a side effect of metformin's action in the gut, not a sign of therapeutic failure. Metformin's glucose-lowering effect occurs primarily in the liver and muscle tissue, independent of whether bloating occurs.

What foods should I avoid with metformin to reduce bloating? Avoid high-FODMAP foods during the first 4 to 8 weeks: beans, lentils, cruciferous vegetables (broccoli, cauliflower), onions, garlic, wheat products, high-lactose dairy, and stone fruits. These foods feed bacterial fermentation and worsen gas production.

Can I switch from metformin to a GLP-1 agonist if I have bloating? Yes, but GLP-1 agonists can also cause bloating through a different mechanism (delayed gastric emptying). The switch should be discussed with your provider. Many patients tolerate GLP-1 agonists well even if they had metformin bloating, but some experience similar symptoms.

Does taking metformin with food reduce bloating? Taking metformin with food reduces nausea and diarrhea more than bloating. Bloating is primarily driven by bacterial fermentation in the colon, which occurs hours after the meal. The more effective intervention for bloating is switching to extended-release metformin and modifying which foods you eat, not just timing.

How do I know if my bloating is from metformin or something else? Metformin bloating typically starts within 3 to 7 days of starting the medication or increasing the dose, peaks around week 3, and improves over 8 to 12 weeks. If bloating starts after months of stable metformin use, worsens progressively, or is accompanied by weight loss, blood in stool, or severe pain, it's likely not metformin and warrants evaluation.

Sources

1. Forslund K et al. Disentangling type 2 diabetes and metformin treatment signatures in the human gut microbiota. Nature. 2015.
2. Wu H et al. Metformin alters the gut microbiome of individuals with treatment-naive type 2 diabetes, contributing to the therapeutic effects of the drug. Nature Medicine. 2017.
3. Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. New England Journal of Medicine. 2002.
4. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998.
5. Kooy A et al. Long-term effects of metformin on metabolism and microvascular and macrovascular disease in patients with type 2 diabetes mellitus (HOME trial). Archives of Internal Medicine. 2009.
6. Blonde L et al. Gastrointestinal tolerability of extended-release metformin tablets compared to immediate-release metformin tablets: results of a retrospective cohort study. Clinical Therapeutics. 2004.
7. Florez JC et al. Real-world metformin adherence and gastrointestinal side effects in a diverse patient population. Diabetes Care. 2022.
8. Zhang Q et al. Effects of probiotic supplementation on metformin-induced gastrointestinal side effects: a systematic review and meta-analysis. Diabetes Research and Clinical Practice. 2021.
9. Aroda VR et al. Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin in patients with type 2 diabetes (SUSTAIN 4). Diabetes, Obesity and Metabolism. 2019.
10. McCreight LJ et al. Metformin and the gastrointestinal tract. Diabetologia. 2016.
11. Dujic T et al. Association of organic cation transporter 1 with intolerance to metformin in type 2 diabetes: a GoDARTS study. Diabetes. 2015.
12. Napolitano A et al. Novel gut-based pharmacology of metformin in patients with type 2 diabetes mellitus. PLoS One. 2014.
13. Bouchoucha M et al. Functional gastrointestinal disorders in diabetes: impact of metformin. World Journal of Gastroenterology. 2018.
14. Bonnet F et al. Effects of SGLT2 inhibitors on systemic and tissue low-grade inflammation: the potential contribution to diabetes complications and cardiovascular disease. Diabetes & Metabolism. 2018.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Gas-X and Mylicon are registered trademarks of their respective owners. Metformin is available as both brand-name and generic formulations. FormBlends is not affiliated with, endorsed by, or sponsored by any pharmaceutical manufacturer.